Literature DB >> 35315926

Forkhead Box Transcription Factors: Double-Edged Swords in Cancer.

Maria Castaneda1, Petra den Hollander1, Sendurai A Mani1.   

Abstract

A plethora of treatment options exist for cancer therapeutics, but many are limited by side effects and either intrinsic or acquired resistance. The need for more effective targeted cancer treatment has led to the focus on forkhead box (FOX) transcription factors as possible drug targets. Forkhead factors such as FOXA1 and FOXM1 are involved in hormone regulation, immune system modulation, and disease progression through their regulation of the epithelial-mesenchymal transition. Forkhead factors can influence cancer development, progression, metastasis, and drug resistance. In this review, we discuss the various roles of forkhead factors in biological processes that support cancer as well as their function as pioneering factors and their potential as targetable transcription factors in the fight against cancer. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35315926      PMCID: PMC9258984          DOI: 10.1158/0008-5472.CAN-21-3371

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  140 in total

Review 1.  Multiple modes of chromatin remodeling by Forkhead box proteins.

Authors:  Avin S Lalmansingh; Sudipan Karmakar; Yetao Jin; Akhilesh K Nagaich
Journal:  Biochim Biophys Acta       Date:  2012-03-02

2.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

3.  Foxo3 Transcription Factor Drives Pathogenic T Helper 1 Differentiation by Inducing the Expression of Eomes.

Authors:  Caroline Stienne; Michaël F Michieletto; Mehdi Benamar; Nadège Carrié; Isabelle Bernard; Xuan-Hung Nguyen; Yannick Lippi; Fanny Duguet; Roland S Liblau; Stephen M Hedrick; Abdelhadi Saoudi; Anne S Dejean
Journal:  Immunity       Date:  2016-10-11       Impact factor: 31.745

4.  Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.

Authors:  Jason S Carroll; X Shirley Liu; Alexander S Brodsky; Wei Li; Clifford A Meyer; Anna J Szary; Jerome Eeckhoute; Wenlin Shao; Eli V Hestermann; Timothy R Geistlinger; Edward A Fox; Pamela A Silver; Myles Brown
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

5.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Authors:  Kristin M Nieman; Hilary A Kenny; Carla V Penicka; Andras Ladanyi; Rebecca Buell-Gutbrod; Marion R Zillhardt; Iris L Romero; Mark S Carey; Gordon B Mills; Gökhan S Hotamisligil; S Diane Yamada; Marcus E Peter; Katja Gwin; Ernst Lengyel
Journal:  Nat Med       Date:  2011-10-30       Impact factor: 53.440

6.  FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Authors:  Xiaoyong Fu; Rinath Jeselsohn; Resel Pereira; Emporia F Hollingsworth; Chad J Creighton; Fugen Li; Martin Shea; Agostina Nardone; Carmine De Angelis; Laura M Heiser; Pavana Anur; Nicholas Wang; Catherine S Grasso; Paul T Spellman; Obi L Griffith; Anna Tsimelzon; Carolina Gutierrez; Shixia Huang; Dean P Edwards; Meghana V Trivedi; Mothaffar F Rimawi; Dolores Lopez-Terrada; Susan G Hilsenbeck; Joe W Gray; Myles Brown; C Kent Osborne; Rachel Schiff
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-06       Impact factor: 11.205

Review 7.  The Role of Forkhead Box 1 (FOXO1) in the Immune System: Dendritic Cells, T Cells, B Cells, and Hematopoietic Stem Cells.

Authors:  Adriana Alicia Cabrera-Ortega; Daniel Feinberg; Youde Liang; Carlos Rossa; Dana T Graves
Journal:  Crit Rev Immunol       Date:  2017       Impact factor: 2.214

8.  Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer.

Authors:  Fei-Fei Kong; Zeng-Qiang Qu; Hai-Hua Yuan; Jiong-Yi Wang; Mei Zhao; Yue-Hui Guo; Jing Shi; Xiao-Di Gong; You-Long Zhu; Feng Liu; Wen-Ying Zhang; Bin Jiang
Journal:  Oncol Rep       Date:  2014-04-04       Impact factor: 3.906

9.  Foxc2 enhances proliferation and inhibits apoptosis through activating Akt/mTORC1 signaling pathway in mouse preadipocytes.

Authors:  Lu Gan; Zhenjiang Liu; Wei Jin; Zhongjie Zhou; Chao Sun
Journal:  J Lipid Res       Date:  2015-06-25       Impact factor: 5.922

10.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

View more
  2 in total

1.  Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.

Authors:  Sweta Ghosh; Rajbir Singh; Zachary Matthew Vanwinkle; Haixun Guo; Praveen Kumar Vemula; Ajay Goel; Bodduluri Haribabu; Venkatakrishna Rao Jala
Journal:  Theranostics       Date:  2022-07-18       Impact factor: 11.600

2.  FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact.

Authors:  Jasna Metovic; Fulvio Borella; Marta D'Alonzo; Nicoletta Biglia; Luca Mangherini; Cristian Tampieri; Luca Bertero; Paola Cassoni; Isabella Castellano
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.